Camzyos (mavacamten) / BMS - LARVOL DELTA

Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy. (PubMed, Rev Cardiovasc Med) - "Indeed, CMIs represent a revolutionary therapeutic paradigm that redefines the standard of care by translating molecular discovery into clinical application. This review provides a guide to the mechanistic basis of sarcomere modulation, summarizes the clinical evidence for mavacamten and aficamten, and critically evaluates the evolving roles of both medications in obstructive and non-obstructive HCM."

Journal • Review • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Effect of Cardiac Myosin Inhibitors on Echocardiographic Features of Cardiac Structure and Function in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. (PubMed, Rev Cardiovasc Med) - "However, the impact of CMIs on the risk of atrial arrhythmias remains unclear. CRD420251243904, https://www.crd.york.ac.uk/PROSPERO/view/CRD420251243904."

Journal • Retrospective data • Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy. (PubMed, Eur J Clin Pharmacol) - No abstract available

Biomarker • Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • CYP2C19

Efficacy and Safety of Mavacamten and Aficamten in Obstructive and Non-obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. (PubMed, Crit Pathw Cardiol) - "CMIs increased adverse events (RR: 1.07 [1.02, 1.13]; p = 0.008), particularly hypertension (RR: 2.19 [1.06, 4.53]; p = 0.03). CMIs improve hemodynamics, functional status, and biomarkers in HCM with an acceptable safety profile and hold promise as disease-modifying therapy, though long-term outcomes require confirmation."

Journal • Retrospective data • Cardiomyopathy • Cardiovascular • Hypertension • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • TNNI3

Brave new drugs, enduring old skills: why surgery still matters in the cardiac myosin inhibitor era. (PubMed, Indian J Thorac Cardiovasc Surg) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Hypertrophic obstructive cardiomyopathy-a cardiologist's perspective. (PubMed, Indian J Thorac Cardiovasc Surg) - "Management options include drugs-beta-blockers, disopyramide, and myosin inhibitors like mavacamten and aficamten. Alcohol septal ablation should be preferred in individuals who are at high surgical risk. In most other patients, both procedures may be considered, and the choice should be based on available resources and patient preferences."

Journal • Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

The new life of myectomy in the era of myosin inhibitors. (PubMed, Prog Cardiovasc Dis) - "Recently, the introduction of cardiac myosin inhibitors, such as mavacamten and aficamten, has reshaped the treatment paradigm for obstructive hypertrophic cardiomyopathy. While cardiac myosin inhibitors offer an effective and less invasive alternative for many patients, they do not fully replace surgical myectomy across all clinical settings. This review articles explores the evolving therapeutic landscape of obstructive hypertrophic cardiomyopathy, focusing on the comparative advantages and limitations of cardiac myosin inhibitors and surgical myectomy."

Journal • Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis. (PubMed, Arch Med Sci Atheroscler Dis) - "Cardiac myosin inhibitors (MIs), including mavacamten and aficamten, offer a novel therapeutic approach for HCM. MIs significantly improve symptomatic, functional, and biomarker outcomes in symptomatic HCM while maintaining an acceptable safety profile, highlighting their potential as a transformative treatment option. Further studies are warranted to evaluate long-term efficacy and safety."

Journal • Retrospective data • Review • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • TNNI3

Association between Baseline Hypertension and Longitudinal Functional Status in Obstructive Hypertrophic Cardiomyopathy Treated with Mavacamten. (PubMed, J Card Fail) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertension • Hypertrophic Cardiomyopathy

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: Bristol-Myers Squibb

New trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Emerging Trends in Hypertrophic Cardiomyopathy Research. (PubMed, Int Heart J) - "Notably, the publications 'Circulation,' 'JACC,' and 'European Heart Journal' recorded the most citations, receiving 30,736, 26,769, and 13,192 citations, respectively. Our study presents the first in-depth bibliometric and visual exploration of the global HCM research landscape, providing an invaluable reference for clinical researchers engaged in this field."

Journal • Review • Cardiomyopathy • Cardiovascular • Heart Failure • Hypertrophic Cardiomyopathy

Comparative Evaluation of the Safety and Efficacy of Transapical Beating-Heart Septal Myectomy versus Mavacamten (CAMZYOS®) in the Treatment of Obstructive Hypertrophic Cardiomyopathy: A Prospective, Multicenter, Randomized Controlled, Superiority Clinical Trial (ChiCTR) - P=N/A | N=128 | Not yet recruiting | Sponsor: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Vass Medical Technology Co. , Ltd

New trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • TNNI3

The improvement and impact of exercise rehabilitation on fatigue in patients with hypertrophic cardiomyopathy after the application of Mavacamten (ChiCTR) - P=N/A | N=60 | Not yet recruiting | Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University

New trial • Cardiomyopathy • Cardiovascular • Fatigue • Hypertrophic Cardiomyopathy

SOAR-HCM: A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China (clinicaltrials.gov) - P=N/A | N=500 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Complete left bundle branch block resolution during treatment with Mavacamten: a case report of a first-in-class scenario. (PubMed, Eur Heart J Case Rep) - "To our knowledge, this is the first reported case of complete left bundle branch block resolution during treatment with mavacamten. This finding contributes to the growing evidence on the positive electrical and structural remodelling deriving from mavacamten use."

Journal • Cardiomyopathy • Cardiovascular • Heart Failure • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

132-WEEK OUTCOMES OF PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY TREATED WITH MAVACAMTEN (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Mavacamten in Obstructive Hypertrophic Cardiomyopathy-A First Australian Experience. (PubMed, Heart Lung Circ) - "Our results provide novel real-world Australian data on the use of mavacamten in patients with oHCM. Approximately 70% of patients experienced significant clinical and echocardiographic improvement in first 6 months after drug initiation, with a tolerable safety profile."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

CARDIAC AMYLOIDOSIS MASQUERADING AS HYPERTROPHIC CARDIOMYOPATHY IN THE AGE OF MAVACAMTEN THERAPY (ACC 2026) - "Abstract is embargoed at this time."

Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

LATE LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION RECURRENCE ON MAVACAMTEN TREATMENT IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (ACC 2026) - "Abstract is embargoed at this time."

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

EFFICACY OF MAVACAMTEN IN HYPERTROPHIC CARDIOMYOPATHY: AN UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (ACC 2026) - "Abstract is embargoed at this time."

Retrospective data • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Covert Transthyretin Amyloidosis Mimicking Advanced Obstructive Hypertrophic Cardiomyopathy Despite Multiple Negative 99mTc-PYP Radionuclide Scans. (PubMed, JACC Case Rep) - "TTR amyloidosis can mimic hypertrophic cardiomyopathy with left ventricular outflow tract obstruction. 99m Technetium pyrophosphate scans are useful to investigate the presence of TTR amyloid, but if suspicion persists despite negative testing, it is reasonable to perform an endomyocardial biopsy."

Journal • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

REAL-WORLD EVIDENCE FROM THE MARVEL-HCM MULTICENTER STUDY OF MAVACAMTEN — A SEX-BASED ANALYSIS OF BASELINE CHARACTERISTICS AND CARDIAC STRUCTURAL AND FUNCTIONAL CHANGES (ACC 2026) - "Abstract is embargoed at this time."

Clinical • HEOR • Real-world • Real-world evidence

MARKED TEMPORAL INCREASE AND GEOGRAPHIC VARIABILITY IN MAVACAMTEN UTILIZATION FOR OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A REAL-WORLD ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

HORIZON-HCM: A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P3 | N=38 | Completed | Sponsor: Bristol-Myers Squibb | Active, not recruiting ➔ Completed

Trial completion • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • TNNI3

COMPARATIVE 1-YEAR OUTCOMES WITH MAVACAMTEN VS SEPTAL REDUCTION IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (ACC 2026) - "Abstract is embargoed at this time."

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy